Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease hepatitis c
Phenotype C0011570|depression
Sentences 30
PubMedID- 24742598 depression and neuroticism in patients with chronic hepatitis c: correlation with peripheral blood mononuclear cells activation.
PubMedID- 21654873 We suggest that interactions between psychobehavioral, genetic, and biological risk factors are of particular importance in the occurrence of depression in patients with hepatitis c taking interferon-α.
PubMedID- 21615916 For instance, ido activity (measured indirectly by the kyn/trp ratio) and an increased neurotoxic potential predict the occurrence of depression in patients with hepatitis c being treated with ifn-α based immunotherapy [34,35].
PubMedID- 21423320 Not only is the prevalence of depression in patients with hepatitis c higher than the general population, antiviral therapy increases the likelihood of a variety of neuropsychiatric complications, including worsening depression, anxiety, and suicidal ideation [28].
PubMedID- 22070000 Objective: the aim of the study was to identify the presence of depression in patients with chronic hepatitis c, predicting factors for its expression, and the impact of depression on the quality of life in these patients.
PubMedID- 24204676 Can antidepressants prevent pegylated interferon-alpha/ribavirin-associated depression in patients with chronic hepatitis c: meta-analysis of randomized, double-blind, placebo-controlled trials.
PubMedID- 25359924 Conclusions: pre-treatment screening for subthreshold depressive and cognitive symptoms will help to identify those at risk for ifn-alpha-associated depression among patients with chronic hepatitis c.
PubMedID- 24778869 Although the interaction between fatigue and depression in patients with chronic hepatitis c infection (hcv) has been recognized, the biological correlates of this observation have yet to be reported.
PubMedID- 23648373 Specific serotonin reuptake inhibitors prevent interferon-alpha-induced depression in patients with hepatitis c: a meta-analysis.
PubMedID- 22075738 Objective: to prospectively evaluate depressive symptoms and risk factors for depression in patients with chronic hepatitis c (chc) treated with pegylated interferon alpha therapy combined with oral ribavirin (peg-ifn-alpha+rbv) and to analyze self-rating scale for depression in comparison to observer-based scale in the given population.
PubMedID- 21691274 Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-alpha-induced depression in patients with chronic hepatitis c.
PubMedID- 24644496 This may be due to less therapeutic options, more social fear and non-significant prognosis of chronic hepatitis c that lead to more depression rate (14, 15).
PubMedID- 25868672 We prospectively evaluate depressive symptoms and risk factors for major depression in patients with hepatitis c virus treated with antiviral combined therapy.
PubMedID- 20569656 The prevalence of depression is increased in patients with chronic hepatitis c virus (hcv) infection.
PubMedID- 23108508 The role of attachment style and depression in patients with hepatitis c.
PubMedID- 23942342 A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis c infection.
PubMedID- 24608155 Interferon-alpha induced depression in a patient with hepatitis c.
PubMedID- 24918850 Interferon-induced depression in patients with hepatitis c: an epidemiologic study.
PubMedID- 25116763 Incidence of depression in patients with chronic hepatitis c receiving combination therapy of pegylated interferon-alpha and ribavirin.
PubMedID- 22326842 depression and anxiety in patients with hepatitis c virus (hcv) infection influence their health-related quality of life and their adherence to antiviral treatment.
PubMedID- 24839091 Serotonin-norepinephrine reuptake inhibitor desvenlafaxine for the treatment of interferon alfa-associated depression in patients with hepatitis c.
PubMedID- 24372654 Objective: to conduct a systematic review and meta-analysis evaluating the efficacy and safety of antidepressant medications for the prevention of interferon-alpha (inf-alpha)-associated depression in patients with chronic hepatitis c virus (hcv).
PubMedID- 24608038 Asymmetric dimethylarginine responses during interferon-alpha-induced depression in patients with chronic hepatitis c infection.
PubMedID- 25670957 Bupropion for interferon-alpha-induced depression in patients with hepatitis c viral infection: an open-label study.
PubMedID- 20587769 Novel treatment strategies for depression in patients with hepatitis c.
PubMedID- 24934987 depression was not associated with hepatitis c (hcv-infected 29%, non-infected 35%; p = 0.25).
PubMedID- 24955454 Conclusions: a history of depression is common with hepatitis c but does not affect initiation of antiviral treatment, despite substantially increased risk of psychiatric side-effects.
PubMedID- 24012293 Conclusion: antidepressant pretreatment with selective serotonin reuptake inhibitors lowers the incidence and severity of ifn-associated depression in patients with chronic hepatitis c infection or malignant melanoma.
PubMedID- 21762832 Screening for depression in patients with hepatitis c using the beck depression inventory-ii: do somatic symptoms compromise validity.
PubMedID- 23139898 Gene expression profiles associated with depression in patients with chronic hepatitis c (ch-c).

Page: 1